New HIV vaccine trial launches in southern africa
NCT ID NCT06617091
First seen Jan 07, 2026 · Last updated May 25, 2026 · Updated 31 times
Summary
This early-stage trial tests a new HIV vaccine called GRAdHIVNE1 in 120 healthy adults, both with and without HIV, in southern Africa. The main goal is to check if the vaccine is safe and to see how well it triggers the immune system. Participants will receive either the vaccine or a placebo, and researchers will monitor them for side effects and immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AHRI
RECRUITINGMtubatuba, KwaZulu-Natal, South Africa
-
DTHF
RECRUITINGCape Town, Western Cape, South Africa
-
Mutala
RECRUITINGHarare, Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.